The aim of this study was to investigate and compare the auditory findings in vestibular migraine (VM) and migraine patients without a history of vertigo.
Introduction
Vestibular migraine (VM) is one of the most common causes of episodic vertigo in adults, with a lifetime prevalence of 1% (1, 2) . Although there are some reports about hearing problems in migraineurs, cochlear symptoms in VM patients have not been widely investigated. This could be due to the recent description criteria of VM in 2001 in which an update took place in 2012 or the fact that the awareness of VM among physicians is low (3, 4) .
Auditory symptoms are generally considered to be less common than vestibular symptoms in migraine (5) . Fluctuating or permanent sudden sensorineural hearing loss has been described in patients with migraine, and these patients typically have other neurological phenomena attributable to vasospasm (6) . Cochlear symptoms have also been reported in vertigo-free migraine patients (7) .
Especially in the early stages of the vestibular disease, the presence of spontaneous and recurrent vertigo attacks accompanying cochlear symptoms might lead to some confusion about the diagnosis. The diagnosis of VM is mainly based on the patient's history, including the main and accompanying symptoms, because currently there is no gold standard and confirmatory test for VM. Definition of the audiological profile of patients with VM might help to solve the diagnostic problems. On the other hand, it is necessary to analyze the audiological profile differences of VM and migraine only (MO) patients.
The aim of this study was to investigate and compare the auditory findings in VM, migraine patients without a history of vertigo (MO patients) and healthy controls.
Methods
This study was approved by the local ethics committee for non-invasive research (2211-GOA). This is a prospective interdisciplinary cross sectional study. Written informed consent was obtained from all patients at the beginning of the study. This study was conducted on 44 patients diagnosed with definite VM according to the modified Neuhauser criteria by Lempert et al. (4) and 31 patients diagnosed as MO according to the International classification of Headache Disorders, 3 rd edition-Beta version who were followed and treated between January 2011 and February 2015 (8) . Also, 52 healthy subjects were included in this study as a control group. Healthy subjects were selected from volunteers with normal hearing thresholds who had no history of vestibular/otological and/or neurological problems. All participants underwent a detailed ENT examination. Before the audiological evaluation, a detailed medical history, interrogating the presence and fluctuation of hearing loss, tinnitus, vertigo, and the relationships of headache and vertigo, was taken from all of the participants. Tinnitus diagnosis was based on patient's anamnesis. For all patients with a tinnitus hemogram, thyroid function tests, lipid panel, vitamin B12 and zinc levels were obtained. Patients with a minimum follow-up time of 6 months were included in the study, and all patients were asked to return if they had any newly developed cochlear symptoms during the follow up period, otherwise all audiological tests were repeated biannually.
The audiological test battery consisted of pure tone audiometry, speech reception threshold, speech recognition score, and acoustic immitancemetry. All audiological examinations were performed during an attack-free period. Air conduction hearing thresholds were evaluated between 250 Hz and 8000 Hz, and bone conduction hearing thresholds were evaluated between 500 Hz and 4000 Hz. The speech reception thresholds and speech discrimination scores were also evaluated (Interacoustics AC 40 Clinical Audiometer; Assens, Denmark). Acoustic immitancemetry tests were performed in all patients (Interacoustics AZ 7 Immitancemeter; Assens, Denmark). Patients with abnormal acoustic immitancemetry findings were excluded from the study.
Statistical analysis
In the descriptive analysis, continuous data were presented as the mean±standard deviation for each of the three groups (VM, MO, and control group). According to Goodman's classification a 0-25 dB HL threshold was accepted as normal hearing (means of 0.5-2 kHz) (9). One-way analysis of variance (ANOVA) and Bonferroni honestly significant difference (HSD) post-hoc tests for multiple comparisons were performed to analyze the audi ological test results between groups. All data were collected and analyzed using the Statistical Package for the Social Sciences version 20.0 (IBM Corp.; Armonk, NY, USA), and p<0.05 was accepted as the level of statistical significance.
Results
There were 44 patients (8 males and 36 females; mean age=36.9±9.2 years) with a mean follow-up time of 3.79±0.59 years (6-48 months) in the VM group. The MO group consisted of 31 patients (3 males, 28 females; mean age=34.5±9.2 years) with a mean follow-up time of 3.85±1.46 years (6-48 months). In the control group there were 13 male and 39 female patients with a mean age of 33.1±13.8 years.
In the VM group, there were 16 patients (36.4%) with tinnitus, while in other groups we did not observe any patients with tinnitus. The rate of tinnitus in the VM group was significantly higher in comparison to the other groups (p<0.05). The mean age of the patients with tinnitus was 37.8 years (18-60 years). All 16 patients had subjective tinnitus, and none of the patients had a history of otologic surgery or acoustic trauma or had recently worked in a noisy environment. For all tinnitus patients, hemograms, thyroid function tests, lipid panels, vitamin B12 and zinc levels were within normal limits. Tinnitus was unilateral in 11 patients and bilateral in 5 patients. None of the patients in any of the groups had permanent or fluctuating hearing loss. Statistical analyses showed that there were no significant differences between the groups in terms of frequency-specific air conduction hearing thresholds or speech recognition scores ( Table 1 , 2) (p>0.05).
Discussion
There are only a few studies and case reports that mention cochlear problems and hearing loss in migraineurs (6, 10) . Fluctuating or permanent sudden sensorineural hearing loss has been described in migraineurs, and these patients typically had accompanying neurological phenomena (such as retinal migraine, hemiplegia, and/or visual aura) that were attributable to vasospasm. Thus, in these patients it is possible to speculate that the sensorineural hearing loss is due to vasospasm occurring in the labyrinthine arteries (6, 10) . In a study conducted on 58 migraineurs and 40 healthy control subjects, no differences were found between the groups in terms of hearing thresholds, but some minor electrophysiological changes, like lowering of the transient evoked otoacoustic emissions (TEAOEs) amplitudes and prolongation of wave III latencies in auditory brainstem response (ABR) were encountered in migraine patients (11) . In a population-based cohort study, it was demonstrated that migraine was a risk factor for the development of sudden sensorineural hearing loss and that the risk was 1.8 times higher than in controls (12) . In our study, no cochlear symptoms were found among migraine patients, and none of them developed any cochlear symptoms during their follow-up period.
The exact mechanism of VM is unknown. Vasospasm in internal auditory arteries, disruption of ion channels in the brain, and cortical spreading depression theory are the main theories on this issue (13) . The most accepted theory is that migraine-induced vasospasm seen in the brain might also occur in the internal auditory arteries causing a decrease in blood flow to the inner ear. Vertiginous symptoms seen in those patients are mostly explained by this event. One might easily speculate that the reduced blood flow in the inner ear might also lead to some cochlear symptoms in those patients, especially over long periods.
The otological symptoms of VM have been reported to include tinnitus, aural fullness, and hearing loss. These symptoms can Turk Arch Otorhinolaryngol 2017; 55: 158-61 be unilateral or bilateral, and the hearing loss patterns can vary from stable to fluctuating, predominantly being low-frequency hearing loss (14) . Hearing loss and tinnitus are not common symptoms of VM, but have been reported in individual patients (15, 16) . In patients with definite VM, the rates of hearing loss vary from 11% to 18% and the rates of tinnitus vary from 20% to 53% (2, (17) (18) (19) .
Differential diagnosis between Meniere's disease and VM with cochlear symptoms is a significant challenge for otolaryngologists due to the overlapping diagnostic criteria. In a study by Gurkov et al. (20) , the authors were able to demonstrate endolymphatic hydrops in 4 of 19 VM patients with cochlear symptoms. Similarly, in another study conducted on 30 VM patients cochlear but no vestibular hydrops was seen in three patients (21) . Therefore, the reason behind sensorineural hearing loss seen in VM patients might be attributable to cochlear hydrops, but it is possible to speculate that these patients might have Meniere's disease and VM simultaneously.
Dieterich and Brandt (22) reported that 16% of 90 patients with VM had auditory symptoms, including hearing loss and tinnitus. In an another study by Radtke et al. (23) , the authors claimed that cochlear symptoms were present in 17 of 47 definite VM patients, and in 8 of these patients symptoms were accompanied with vertigo episodes. In one study, the VM patient group was longitudinally followed for 9 years and it was reported that the rate of cochlear symptoms in these patients was increased from 15% to 49% as time went by. It was also noted that half of the patients had cochlear symptoms with vertigo attacks and that seven of the patients developed bilateral hearing loss during the follow-up period (24) .
In our study, we did not observe any hearing loss in any of the VM patients during their follow up, but 16 (36.4%) of them had tinnitus. Therefore, we thought that the increased incidence of tinnitus in VM patients could be an indicator of cochlear and/or auditory nerve involvement in these patients. We did not have any patients who had or developed hearing loss during the follow up period. One possible explanation for this might be our relatively short (6-48 months) follow up time, which we see as a potential weakness of our study. Therefore, we think that patients, especially those with tinnitus, should be closely followed up for the development of possible hearing loss or other cochlear symptoms in the future.
Conclusion
In our study, we did not find any cochlear problems in migraine patients, however a significant rate (36.4%) of tinnitus was seen in the VM group. Even though we did not encounter any VM patients with hearing loss, further studies with longer follow up time are needed to justify the occurrence of possible hearing loss in those patients in the long term.
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